文献速递湿疹皮炎与荨麻疹

克立硼罗治疗特应性皮炎:瘙痒与生活质量关联分析

Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-07-07

BACKGROUND: Pruritus is a leading cause of reduced health-related quality of life (QoL) in atopic dermatitis (AD). Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD.…

要点

  • 瘙痒严重度SPS与DLQI、CDLQI、DFI均呈线性关系。
  • SPS 0分对应无负面影响,3分对应极大影响生活质量。
  • 改善瘙痒可能直接提升患者及照护者生活质量。

核心结论

  • SPS与DLQI、CDLQI和DFI的关系证实瘙痒与特应性皮炎患者及照护者生活质量显著相关。

研究设计与样本

  • 汇总两项相同III期研究(NCT02118766、NCT02118792)数据,患者≥2岁随机2:1接受克立硼罗或赋形剂每日两次共28天。

主要发现

  • DLQI分析n=294,CDLQI分析n=1200,DFI分析n=1293,SPS与各QoL指标线性关系成立。
  • SPS评分0、1、2、3分别对应DLQI无负面影响、小影响、中等影响、极大影响。
  • SPS与CDLQI和DFI的关系模式与DLQI相似。

关键数值与推荐

  • SPS为4点量表:0为无瘙痒,3为烦人的瘙痒/搔抓干扰睡眠。
  • QoL测量:DLQI用于≥16岁患者,CDLQI用于2-15岁患者,DFI用于2-17岁患者的照护者。

临床怎么用

  • 临床可依据SPS评分快速评估瘙痒对生活质量的影响程度。
  • 治疗中应重视瘙痒控制以改善患者及照护者的生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pruritus is a leading cause of reduced health-related quality of life (QoL) in atopic dermatitis (AD). Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD. In identical Phase 3 studies (NCT02118766, NCT02118792), crisaborole reduced disease and pruritus severity versus vehicle. OBJECTIVE: Quantify the relationship between pruritus and QoL using data from these studies. METHODS: Patients aged ≥2 years were randomly assigned 2 : 1 to receive crisaborole:vehicle twice daily for 28 days. QoL was measured at baseline and day 29 using the Dermatology Life Quality Index (DLQI; patients aged ≥16 years), the Children's Dermatology Life Quality Index (CDLQI; patients aged 2-15 years) and the Dermatitis Family Impact (DFI; caregivers of patients aged 2-17 years). Pruritus was measured using the Severity of Pruritus Scale (SPS), a 4-point scale from 0 ('no itching') to 3 ('bothersome itching/scratching that disturbs sleep'), and captured morning and evening via electronic diary. Data from crisaborole and vehicle arms were pooled for this analysis. A repeated-measures longitudinal model was used to estimate relationships between pruritus (SPS) and QoL (DLQI, CDLQI and DFI in separate analyses). RESULTS: One thousand five hundred and twenty two patients received crisaborole or vehicle. A linearity assumption for the relationship between SPS and DLQI (n = 294), CDLQI (n = 1200), and DFI (n = 1293) was appropriate. For DLQI, SPS score of 0 was associated with 'no negative effect on patient QoL'; SPS score of 1 was associated with 'small effect on patient QoL'; SPS score of 2 was associated with 'moderate effect on patient QoL'; and SPS score of 3 was associated with 'very large effect on patient QoL'. The pattern of relationships between SPS and CDLQI and DFI was similar. CONCLUSIONS: The relationships between SPS and DLQI, CDLQI and DFI substantiate the significant link between pruritus and patient/caregiver QoL in AD.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Ständer S, Yosipovitch G, Bushmakin AG, et al. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole. J Eur Acad Dermatol Venereol. 2019. PMID: 31132182. doi:10.1111/jdv.15712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。